Increased level of RPA1 and reduced level of HSPA5/GRP78 were the most prominent secretory features of vemurafenib-resistant colon cancer cells, which were also specifically correlated with BRAFV600E genotype and poor survival outcomes in colon cancer patients with BRAFV600E mutation. Here, RPA1 is linked to malignant colon neoplasm.